Exploring High Growth Tech Stocks for December 2024

In This Article:

As global markets experience fluctuations, with U.S. stocks facing declines due to cautious Federal Reserve commentary and political uncertainty, the focus on high growth tech stocks becomes particularly relevant for investors seeking potential opportunities amidst broader market volatility. In such an environment, identifying a promising stock often involves looking at companies with innovative technologies and strong growth prospects that can navigate economic challenges and capitalize on market trends.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Material Group

20.45%

24.01%

★★★★★★

Seojin SystemLtd

35.41%

39.86%

★★★★★★

Yggdrazil Group

30.20%

87.10%

★★★★★★

eWeLLLtd

27.24%

28.74%

★★★★★★

Ascelia Pharma

76.15%

47.16%

★★★★★★

Medley

25.57%

31.67%

★★★★★★

Waystream Holding

22.09%

113.25%

★★★★★★

CD Projekt

24.92%

27.00%

★★★★★★

Fine M-TecLTD

36.52%

131.08%

★★★★★★

JNTC

29.48%

104.37%

★★★★★★

Click here to see the full list of 1276 stocks from our High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Valneva

Simply Wall St Growth Rating: ★★★★★☆

Overview: Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet needs, and it has a market cap of €310.78 million.

Operations: Valneva SE focuses on the development, production, and sale of vaccines targeting infectious diseases that lack adequate prevention options. The company's revenue is primarily generated from its vaccine portfolio, although specific segment data is not detailed.

Valneva SE, amid a challenging backdrop of being unprofitable with a volatile share price, is navigating its path towards profitability with an expected revenue growth rate of 24.6% per year, outpacing the French market's 5.5%. This growth is underpinned by strategic moves like the recent licensing agreement with Serum Institute of India for its chikungunya vaccine during one of India's worst outbreaks, coupled with a $41.3 million funding boost from CEPI and the EU. Despite shareholder dilution over the past year and less than a year's cash runway posing financial constraints, Valneva's innovative strides in infectious diseases—evidenced by its robust R&D spending which remains crucial for future approvals and market expansions—are setting it apart in high-stakes markets.

ENXTPA:VLA Revenue and Expenses Breakdown as at Dec 2024
ENXTPA:VLA Revenue and Expenses Breakdown as at Dec 2024

Empyrean Technology

Simply Wall St Growth Rating: ★★★★★☆